Specific immunotherapy (SIT) is an efficient treatment of allergic diseases to defined allergens. Despite being used in clinical practice since early in this century, more rational and safer regimens are required, because SIT is faced with the risk of anaphylaxis and standardization problems of allergen-extract-based treatments. A better understanding of the pathogenesis of allergy and of the mechanisms of SIT has led to various approaches to overcome these problems. Knowledge of the influence of IgE-facilitated antigen presentation on allergen-specific Th2 responses increased the efforts to generate non-IgE-binding allergens. The current principal approach to allergen modification is to modify B cell epitopes in order to prevent IgE binding and effector cell cross-linking while preserving T cell epitopes to retain the capacity of inducing tolerance. In this way, the modified allergen will be directed to T cells by a phagocytosis/pinocytosis-mediated antigen uptake mechanism, bypassing IgE cross-linking and IgE-dependent antigen presentation. Accordingly, a differential regulation of allergen-specific T cell cytokine patterns and IgE:IgG production was demonstrated by modifications of the three-dimensional structure of allergens because of linearity in T cell epitopes and conformation dependence in B cell epitopes. In this context, chemically modified allergen extracts with low IgE-binding capacity have been developed to reduce anaphylactic side effects since the early 1980s. The progress of recombinant techniques for producing allergens and allergen derivatives has led to a dramatic improvement in the ability of developing novel vaccines for the treatment of allergy. This has enabled mutation or deletion of decisive amino acids in B cell epitopes and fractionation or oligomerization of allergens by genetic engineering as fruitful approaches to generate hypoallergenic vaccines. Moreover, non-IgE-binding short T cell epitope peptides and single-amino-acid-altered peptide ligands represent potential candidates for future SIT.

Keywords:
Modified allergens, Recombinant allergens, Antigen conformation, Antigen presentation, IgE regulation, Th1/Th2
1.
Hopkin JM: Mechanisms of enhanced prevalence of asthma and atopy in developed countries. Curr Opin Immunol 1997;9:788–792.
2.
Bentley AM, Jacobson MR, Cumberworth V, Barkans JR, Moqbel R, Schwartz LB: Immunohistology of the nasal mucosa in seasonal allergic rhinitis: Increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992;89:877–883.
3.
Nish WA, Charlesworth EN, Davis TL, Whisman BA, Valtier S, Charlesworth MG, Leiferman KM: The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 1994;93:484–493.
4.
Bousquet J, Lockey RF, Malling HJ: WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998;53:S1–S42.
5.
Müller UR, Mosbech H: Position paper: Immunotherapy with hymenoptera venoms. Allergy 1993;48:36–46.
6.
Müller UR, Hebling A, Berchtold E: Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529–535.
7.
Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR: Grass pollen immunotherapy: Efficacy and safety during a 4-year follow-up study. Allergy 1995;50:405–413.
8.
Varney VA, Gaga M, Frew AJ: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergic drugs. Br Med J 1991;302:489–500.
9.
Akdis CA, Blaser K: IL-10 induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy. FASEB J 1999;13:603–609.
10.
Durham SR, Till SJ: Immunological changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157–164.
11.
Ebner C: Immunological mechanisms operative in allergen-specific immunotherapy. Int Arch Allergy Immunol 1999;119:1–5.
12.
Hussain R, Poindexter RW, Ottesen EA: Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass. J Immunol 1992;148:2731–2739.
13.
Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL: Seasonal asthma in northern California: Allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986;78:590–600.
14.
Wetterwald A, Skvaril F, Müller U, Blaser K: Isotypic and idiotypic characterization of anti-bee venom phospholipase A2 antibodies. Arch Allergy Appl Immunol 1985;77:195–197.
15.
van Neerven RJJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum IgE-facilitated allergen presentation. J Immunol 1999;163:2944–2952.
16.
Rocklin RE, Sheffer A, Greineder DK, Melmon KL: Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980;302:1213–1219.
17.
Creticos PS, Franklin Adkinson N Jr, Kagey-Sabotka A, Proud D, Meier HL, Naclerio RM, Lichtenstein LM, Norman PS: Nasal challenge with ragweed in hay fever patients: Effect of immunotherapy. J Clin Invest 1983;76:2247–2253.
18.
Rak S, Rowhagen O, Venge P: The effect of immunotherapy on bronchial hyper-responsiveness and eosinophil cationic protein in pollen allergic patients. J Allergy Clin Immunol 1988;82:470–480.
19.
Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M: Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991;21:115–120.
20.
Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen stimulated T cell cultures. J Immunol 1995;154:4178–4194.
21.
Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT: Allergen immunotherapy decreases interleukin 4 production in CD4 T cells from allergic individuals. J Exp Med 1993;178:2123–2130.
22.
Durham SR, Walker SM, Varga E-V, Jacobson MR, O’Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. New Engl J Med 1999;341:468–475.
23.
Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J: Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131–1139.
24.
Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Müller U, Blaser K: Epitope specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:1676–1683.
25.
Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K: Role of IL-10 in specific immunotherapy. J Clin Invest 1998;102:98–106.
26.
Müller UR, Akdis AC, Fricker M, Akdis M, Bettens F, Blesken T, Blaser K: Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immunol 1998;101:747–754.
27.
Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sabotka A, Lichtenstein LM, Essayan DM: Effects of peptide therapy on ex vivo T cell responses. J Allergy Clin Immunol 1998;101:506–513.
28.
Parijs LV, Abbas AK: Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science 1998;280:243–247.
29.
Essery G, Feldmann M, Lamb J: Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology 1988;64:413–417.
30.
Lanzavecchia A: Mechanisms of antigen uptake for presentation. Curr Opin Immunol 1996;8:348–354.
31.
Berzofsky JA, Brett SJ, Streicher HZ, Takahashi H: Antigen processing for presentation to T lymphocytes: Function, mechanisms, and implications for the T-cell repertoire. Immunol Rev 1988;106:5–31.
32.
Pierce SK, Morris JF, Grusby MJ, Kaumaya P, Buskirk AV, Srinivasan M, Crump B, Smolenski LA: Antigen-presenting function of B lymphocytes. Immunol Rev 1988;106:149–180.
33.
DeKruyff RH, Fang Y, Umetsu DT: IL-4 synthesis by in vivo primed keyhole limpet hemocyanin specific CD4+ T cells. I. Influence of antigen concentration and antigen-presenting cell type. J Immunol 1992;149:3468–3476.
34.
Secrist H, DeKruyff RH, Umetsu DT: Interleukin-4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081–1089.
35.
Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:142–146.
36.
Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227–257.
37.
Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994;76:241–251.
38.
Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher JH: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995;80:707–718.
39.
Pistoia V: Production of cytokines by human B cells in health and disease. Immunol Today 1997;18:343–350.
40.
Matthes T, Werner-Favre C, Tang H, Zhang X, Kindler V, Zubler HR: Cytokine mRNA expression during an in vitro response of human B lymphocytes: Kinetics of B cell tumor necrosis factor α, interleukin (IL)6, IL-10, and transforming growth factor β 1 mRNAs. J Exp Med 1993;178:521–528.
41.
Rissoan M-C, Soumelis V, Kadowaki N, Grouard G, Briere F, De Waal Malefyt R, Liu Y-J: Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183–1186.
42.
Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K: Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998;28:914–925.
43.
Kagey-Sabotka A, Franklin RM, Adkinson NF Jr, Valentine M, Bauer H, Lichtenstein LM: Allergy to insect sting. II. Phospholipase A: The major allergen in honey bee venom. J Allergy Clin Immunol 1976;57:29–40.
44.
Müller UR, Dudler T, Schneider T, Crameri R, Fischer H, Skrbic D, Maibach R, Blaser K, Suter M: Type 1 skin reactivity to native and recombinant phospholipase A2 from honey bee venom is similar. J Allergy Clin Immunol 1995;96:395–402.
45.
Akdis CA, Blesken T, Akdis M, Alkan SS, Wüthrich B, Heusser CH, Blaser K: Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and non-specific activation of T and B cells. J Allergy Clin Immunol 1997;99:345–352.
46.
Akdis CA, Blesken T, Akdis M, Alkan SS, Heusser CH, Blaser K: Glucocorticoids inhibit human antigen-specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro. Eur J Immunol 1997;27:2351–2357.
47.
Blaser K, Carballido JM, Faith A, Crameri R, Akdis CA: Determinants and mechanisms of human immune response to bee venom phospholipase A2. Int Arch Allergy Immunol 1998;117:1–10.
48.
Scott DL, Otwinowski Z, Gelb MH, Sigler PB: Crystal structure of BV phospholipase A2 in a complex with a transition-state analogue. Science 1990;250:1563–1566.
49.
Dudler T, Chen W, Wang S, Schneider T, Annand R, Dempcy R, Crameri R, Gmachl M, Suter M, Gelb M: High level expression in Escherichia coli and rapid purification of enzymatically active honey BV phospholipase A2. Biochim Biophys Acta 1992;1165:201–210.
50.
Schneider T, Lang AB, Carballido JM, Santamaria Babi LF, Dudler T, Kägi MK, Blaser K, Suter M: Human monoclonal and polyclonal antibodies recognize predominantly discontinuous epitopes on BV phospholipase A2. J Allergy Clin Immunol 1994;94:61–69.
51.
Aalberse RC, Van der Gaag R, van Leuwen J: Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983;130:722–726.
52.
Carballido JM, Carballido-Perrig N, Kägi MK, Meloen RH, Wüthrich B, Heusser CH, Blaser K: T cell epitope specificity in human allergic and non-allergic subjects to bee venom phospholipase A2. J Immunol 1993;150:3582–3591.
53.
Vailes LD, Ying L, Bao Y, DeGroot H, Aalberse RC, Chapman MD: Fine specificity of B-cell epitopes on Felis domesticus allergen I (Fel d I): Effect of reduction and alkylation and deglycosilation on Fel d I structure and antibody binding. J Allergy Clin Immunol 1994;93:22–33.
54.
Olsson S, van Hage-Hamsten M, Whitley P: Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor. Mol Immunol 1998;35:1017–1023.
55.
Carballido JM, Faith A, Carballido-Perrig N, Blaser K: The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific Th cells. Eur J Immunol 1997;27:515–521.
56.
Yang X, Gieni RS, Mosmann TR, Hayglass KT: Chemically modified antigen preferentially elicits induction of Th1-like cytokine synthesis patterns in vivo. J Exp Med 1993;178:349–353.
57.
Kehry MR, Yamashita LC: Low-affinity IgE receptor (CD23) function on mouse B cells: Role in IgE-dependent antigen focusing. Proc Natl Acad Sci USA 1989;86:7556–7560.
58.
Stigl G, Maurer D: IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Int Arch Allergy Immunol 1997;113:24–29.
59.
Kinet J-P: Atopic allergy and other hypersensitivities. Curr Opin Immunol 1999;11:603–605.
60.
Schmitt DA, Bieber T, Cazenave JP, Hanau D: Fc receptors of human langerhans cells. J Invest Dermatol 1990;94:15S–21S.
61.
Maurer D, Stigl G: Immunoglobulin E-binding structures on antigen-presenting cells present in skin and blood. J Invest Dermatol 1995;104:707–710.
62.
Van der Heijden FL, van Neerven RJJ, van Katwijk M, Bos JD, Kapsenberg ML: Serum IgE-facilitated allergen presentation in allergic disease. J Immunol 1993;150:3643–3647.
63.
Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G: The high affinity IgE receptor (FceRI) mediates IgE-dependent allergen presentation. J Immunol 1995;154:6285–6289.
64.
Pirron U, Schlunck T, Prinz JC, Rieber EP: IgE-dependent antigen focussing by human B lymphocytes is mediated by the low-affinity receptor for IgE. Eur J Immunol 1990;20:1547–1551.
65.
Santamaria LF, Bheekha R, Van Reijsen FC, Perez Soler MT, Suter M, Bruijnzeel-Koomen CAFM, Mudde GC: Antigen focusing by specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr virus-transformed B cells. Hum Immunol 1993;37:23–30.
66.
Akdis CA, Akdis M, Simon D, Dibbert B, Weber M, Gratzl S, Kreyden O, Disch R, Wüthrich B, Blaser K, Simon H-U: T cells and T-cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 1999;113:628–634.
67.
Achatz G, Nitschke L, Lamers MC: Effect of transmembrane and cytoplasmic domains of IgE on the IgE response. Science 1977;276:409–411.
68.
Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reinmann J, Fick RB, Boushey HA: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828–1833.
69.
Coyle AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C: Central role of immunoglobulin-E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996;183:1303–1308.
70.
Norman PS, Winkenwerder WL, D’Lugoff BC: Controlled evaluations of repository therapy in ragweed hay fever. J Allergy 1967;39:82–88.
71.
Norman PS, Winkenwerder WL, Lichtenstein LM: Trials of alum-precipitated pollen extracts in the treatment of hay fever. J Allergy Clin Immunol 1972;59:31–36.
72.
Ishizaka K, Okudaira H, King TP: Immunogenic properties of modified antigen E. II. Ability of urea denaturated antigen and polypeptide chain to prime T-cells specific for antigen E. Eur J Immunol 1975;114:110–115.
73.
Lee WY, Sehon AH: Abrogation of reaginic antibodies with modified proteins. Nature 1977;267:618–620.
74.
Juniper EF, O’Connor J, Roberts RS, Hargreave FE: A two year study of Pegalgen (a polyethylene glycol modified ragweed extract) in ragweed rhinoconjunctivitis. J Allergy Clin Immunol 1983;71:119.
75.
Butterfield JH, Gleich GJ, Yinginger JW, Zimmerman EM, Reed CE: Immunotherapy with short ragweed fraction A:D-glutamic acid:D-lysine polymer in ragweed hay fever. J Allergy Clin Immunol 1981;67:272–276.
76.
Grammer LC, Zeiss CR, Suszko IM, Shaughnessy MA, Patterson R: A double-blind, placebo controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy . J Allergy Clin Immunol 1982;69:494–499.
77.
Weber AE, Blaser K: Suppression of the anti-hapten IgE antibody response with hapten-modified spleen cells. Eur J Immunol 1986;16:1527–1531.
78.
Marsh DG, Norman PS, Roebber M, Lichtenstein LM: Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981;68:449–459.
79.
Grammer LC, Shaughnessy MA, Patterson R: Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985;76:397–401.
80.
Meriney KD, Kothari H, Chinoy P, Grieco HM: The clinical and immunological efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Ann Allergy 1986;56:34–39.
81.
Bousquet J, Braquemond P, Feinberg J, Guerin B, Maasch HJ, Michel FB: Specific IgE response with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy 1986;56:456–459.
82.
Bousquet J, Frank E, Hejjaoui A, Maasch HJ, Michel FB, Soussana M: Double-blind, placebo-controlled immunotherapy with high-molecular-weight, formalinized allergoid in grass pollen allergy. Int Arch Allergy Appl Immunol 1987;82:550–552.
83.
Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, Canonica GW: Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629–632.
84.
Circovic TD, Bucilica MN, Gavrovic MD, Vujcic Z, Petrovic S, Jankov RM: Physicochemical and immunologic characterization of low-molecular weight allergoids of Dactylis glomerata pollen proteins. Allergy 1999;54:128–134.
85.
Ferreira F, Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, Grimm RG, Jahn-Schmid B, Breiteneder H, Kraft D, Breitenbach M, Rheinberger H-J, Scheiner O: Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy. FASEB J 1998;12:231–242.
86.
Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, Grimm R, Hoffmann-Sommergruber K, Scheiner O, Kraft D, Breitenbach M, Rheinberger H-J, Ebner C: Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: Potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996;183:599–608.
87.
Schramm G, Kahlert H, Suck R, Weber B, Stüwe H-T, Müller W-D, Bufe A, Becker W-M, Schlaak MW, Jäger L, Cromwell O, Fiebig H: ‘Allergen engineering’: Variants of the timothy grass pollen allergen Phl p 5b with reduced IgE binding capacity but conserved T cell reactivity. J Immunol 1999;162:2406–2414.
88.
Hakkart GAJ, Aalberse RC, Van Ree R: Epitope mapping of the house-dust-mite allergen Der p 2 by means of site-directed mutagenesis. Allergy 1998;53:165–172.
89.
Burks AW, King N, Bannon GA: Modification of a major peanut allergen leads to loss of IgE binding. Int Arch Allergy Immunol 1999;118:313–314.
90.
Shin D, Compadre CM, Maleki SJ, Kopper RA, Sampson H, Huang SK, Burks AW, Bannon GA: Bichemical and structural analysis of the IgE binding sites on Ara h 1, an abundant and highly allergenic peanut protein. J Biol Chem 1998;273:13753–13759.
91.
Yasue M, Yokota T, Fukada M, Takai T, Suko M, Okudaira H, Okumura Y: Hyposensitization to allergic reaction in rDer f 2-sensitized mice by the intranasal administration of a mutant of rDer f 2, C8/119S. Clin Exp Immunol 1998;113:1–9.
92.
Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler H-G, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R: Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99:1673–1681.
93.
Zeiler T, Taivainen A, Rytkonen M, Rautiainen J, Karjalainen H, Mantyjarvi R, Tuomisto L, Virtanen T: Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J Allergy Clin Immunol 1997;100:721–727.
94.
van Hage-Hamsten M, Kronqvist M, Zetterström O, Johansson E, Niederberger V, Vrtala S, Grönlund H, Grönneberg R, Valenta R: Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999;104:969–977.
95.
Paoli G, Purohit A, Oster J-P, De Blay F, Vrtala S, Niederberger V, Kraft D, Valenta R: Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v1 wildtype by skin prick and intradermal testing: Results obtained in a French population. Clin Exp Allergy, in press.
96.
Nopp A, Hallden G, Lundahl J, Johansson E, Vrtala S, Valenta R, Grönnecerg R, van Hage-Hamsten M: Genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, induce less eosinophilic activity in skin chamber fluids collected from birch pollen allergic patients than rBet v 1 wild type. Int Arch Allergy Immunol, in press.
97.
Vrtala S, Hirtenlehner K, Susani M, Hufnagl P, Binder BR, Vangelista L, Pastore A, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R: Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: Candidates for specific immunotherapy. Int Arch Allergy Immunol 1999;118:218–219.
98.
Haselden BM, Kay AB, Larche M: Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999;189:1885–1894.
99.
Hoyne GF, O’Hehir R, Wraith DC, Thomas WR, Lamb JR: Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993;178:1783–1788.
100.
Briner T, Kou M, Keating K, Rogers B, Greenstein J: Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993;90:7608–7612.
101.
Norman P, Ohmann JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, Wood R, Eggleston P, Lichtenstein LM, Jones N: Treatment of cat allergy with T cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623–1628.
102.
Evavold BD, Allen PM: Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991;252:1308–1310.
103.
Faith A, Akdis CA, Akdis M, Joss A, Wymann D, Blaser K: An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling. J Immunol 1999;162:1836–1842.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.